从“制药大国”到“制药强国”加速转变 向新而行国产创新药蓬勃发展

中国产业经济信...
Aug 04

今年5月,三生制药与辉瑞达成60.5亿美元授权协议,刷新了中国创新药单笔交易纪录。与此同时,迪哲医药自主研发的舒沃替尼在美国实现“零发补”获批,成为中国首个独立研发并在美上市的全球首创新药(FIC)。这仅仅是中国创新药行业2025年上半年蓬勃发展的缩影。数据显示,2025年上半年中国创新药领域达成超50笔全球合作,总额达484.48亿美元;154款新药获批临床,16款创新药成功上市,77款药物获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10